Siu Kit Lam
Directeur Technique/Scientifique/R&D chez Immunophotonics, Inc.
Postes actifs de Siu Kit Lam
Sociétés | Poste | Début | Fin |
---|---|---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Directeur Technique/Scientifique/R&D | - | - |
Historique de carrière de Siu Kit Lam
Formation de Siu Kit Lam
University of Washington | Doctorate Degree |
The Johns Hopkins University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 4 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectorielle
Consumer Services | 3 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
- Bourse
- Insiders
- Siu Kit Lam
- Expérience